Last reviewed · How we verify
Rosuvastatin; improvement of lipid profile
Rosuvastatin; improvement of lipid profile is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary heart disease.
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides while raising HDL cholesterol.
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides while raising HDL cholesterol. Used for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary heart disease.
At a glance
| Generic name | Rosuvastatin; improvement of lipid profile |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rosuvastatin is a competitive inhibitor of HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. By blocking this enzyme, the drug decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL particles from the bloodstream. This results in significant reductions in total cholesterol, LDL cholesterol, and triglycerides, with modest increases in HDL cholesterol.
Approved indications
- Hypercholesterolemia and mixed dyslipidemia
- Primary prevention of cardiovascular disease in at-risk patients
- Secondary prevention of cardiovascular events in patients with established coronary heart disease
Common side effects
- Myalgia (muscle pain)
- Headache
- Elevated liver enzymes (ALT/AST)
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin; improvement of lipid profile CI brief — competitive landscape report
- Rosuvastatin; improvement of lipid profile updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Rosuvastatin; improvement of lipid profile
What is Rosuvastatin; improvement of lipid profile?
How does Rosuvastatin; improvement of lipid profile work?
What is Rosuvastatin; improvement of lipid profile used for?
Who makes Rosuvastatin; improvement of lipid profile?
What drug class is Rosuvastatin; improvement of lipid profile in?
What development phase is Rosuvastatin; improvement of lipid profile in?
What are the side effects of Rosuvastatin; improvement of lipid profile?
What does Rosuvastatin; improvement of lipid profile target?
Related
- Drug class: All HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia and mixed dyslipidemia
- Indication: Drugs for Primary prevention of cardiovascular disease in at-risk patients
- Indication: Drugs for Secondary prevention of cardiovascular events in patients with established coronary heart disease
- Compare: Rosuvastatin; improvement of lipid profile vs similar drugs
- Pricing: Rosuvastatin; improvement of lipid profile cost, discount & access